buprenorfin alkaloid-int 2 mg podjezične tablete
alkaloid - int d.o.o. - buprenorfin - podjezična tableta - buprenorfin 2 mg / 1 tableta - buprenorfin
tantum verde 1,5 mg/ml raztopina za grgranje in izpiranje ust
angelini pharma Ősterreich gmbh - benzidamin - tekočina za grgranje/izpiranje ust - benzidamin 1,34 mg / 1 ml - benzidamin
riximyo
sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastična sredstva - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z rituksimabom ali bolniki, ognjevzdržni, da prejšnji rituksimabom plus kemoterapijo. glej oddelek 5. 1 za nadaljnje informacije. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabom je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).
bimatoprost stada 0,1 mg/ml kapljice za oko, raztopina
stada arzneimittel ag - bimatoprost - kapljice za oko, raztopina - bimatoprost 0,1 mg / 1 ml - bimatoprost
duloksetin actavis 40 mg trde gastrorezistentne kapsule
actavis group ptc ehf. - duloksetin - gastrorezistentna kapsula, trda - duloksetin 40 mg / 1 kapsula - duloksetin
kalijev jodid lek 65 mg tablete
lek d.d. - kalijev jodid - tableta - kalijev jodid 65 mg / 1 tableta - kalijev jodid
kalijev jodid lek 65 mg tablete
lek d.d. - kalijev jodid - tableta - kalijev jodid 65 mg / 1 tableta - kalijev jodid
kalijev jodid lek 65 mg tablete
lek d.d. - kalijev jodid - tableta - kalijev jodid 65 mg / 1 tableta - kalijev jodid
methotrexate for injection usp 1g
kemofarmacija d.d. - raztopina za injiciranje - metotreksat
ralago 1 mg tablete
krka, d.d., novo mesto - razagilin - tableta - razagilin 1 mg / 1 tableta - razagilin